See more : Federal Home Loan Mortgage Corporation (FMCCT) Income Statement Analysis – Financial Results
Complete financial analysis of Zynerba Pharmaceuticals, Inc. (ZYNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zynerba Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Beluga NV (BELU.BR) Income Statement Analysis – Financial Results
- National Fertilizers Limited (NFL.BO) Income Statement Analysis – Financial Results
- Neelamalai Agro Industries Limited (NEAGI.BO) Income Statement Analysis – Financial Results
- DCM Shriram Industries Limited (DCMSRMIND.BO) Income Statement Analysis – Financial Results
- Superactive Group Company Limited (0176.HK) Income Statement Analysis – Financial Results
Zynerba Pharmaceuticals, Inc. (ZYNE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zynerba.com
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.10M | 21.42M | 35.65M | 20.38M | 27.25M | 22.81M | 16.78M | 7.45M | 2.40M | 1.13M |
| General & Administrative | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Cost & Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Interest Income | 846.86K | 21.05K | 243.99K | 1.52M | 961.32K | 519.55K | 80.22K | 0.00 | 0.00 | 0.00 |
| Interest Expense | -215.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 631.13K | 559.68K | -481.72K | 145.91K | 99.57K | 94.21K | 75.30K | 26.03K | 27.06K | 49.39K |
| EBITDA | -34.62M | -36.21M | -52.06M | -34.17M | -40.40M | -32.82M | -23.21M | -12.51M | -5.64M | -585.05K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,422.28% | -456,747.03% | -316,123.92% | -4,483.73% | -696.37% | -61.98% |
| Operating Income | -35.25M | -36.77M | -52.06M | -34.32M | -40.40M | -32.82M | -23.21M | -12.53M | -5.67M | -634.44K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,974.22% | -452,731.16% | -320,105.21% | -4,493.07% | -699.71% | -67.21% |
| Total Other Income/Expenses | 215.73K | -538.63K | 725.71K | 1.38M | 486.66K | 810.71K | -208.42K | 7.35K | -1.84K | -2.35K |
| Income Before Tax | -35.04M | -37.31M | -51.34M | -32.94M | -39.91M | -32.01M | -23.42M | -12.52M | -5.67M | -636.79K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,980.00% | -4,490.43% | -699.94% | -67.46% |
| Income Tax Expense | -215.73K | 291.49K | -932.75K | -1.51M | 486.66K | -27.54K | -27.54K | 27.54K | 0.00 | 0.00 |
| Net Income | -34.82M | -37.60M | -50.40M | -31.43M | -39.91M | -32.01M | -23.39M | -12.55M | -5.67M | -636.79K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,600.10% | -4,500.30% | -699.94% | -67.46% |
| EPS | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| EPS Diluted | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| Weighted Avg Shares Out | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
| Weighted Avg Shares Out (Dil) | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
8 Cannabis Stocks on Fire After Corporate Moves
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.
Zynerba's CBD skin gel Zygel offers a goldmine of therapies for Fragile X syndrome and other conditions
Developing novel transdermal CBD treatments to treat patients suffering rare epilepsies and neurological disorders Lead development candidate Zygel offers a potential goldmine of therapies for multiple conditions Zygel is being developed for patients suffering from Fragile X syndrome, a genetic condition...
Zynerba Pharmaceuticals says it is fully funded into 2024; lays out plans to advance four Zygel indications in 4Q results
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) believes its operations and capital requirements to be fully funded into 2024, the company announced as part of its fourth-quarter and full-year results published Wednesday. As of December 31, the company had $59.2 million in...
Zynerba Pharmaceuticals says its fully funded into 2024, lays out plans to advance four Zygel indications in 4Q results
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) believes its operations and capital req[uirements to be fully funded into 2024, the company announced as part of its fourth quarter and full-year results published Wednesday. As of December 31, the company had $59.2 million in...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
DEVON, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December...
Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.
Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33rd Annual ROTH Conference,...
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.
ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today
ZYNE stock is on a roll, with investors betting its transdermal therapeutic cannabidiol gel will take off soon. The post ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today appeared first on InvestorPlace.
ZYNE Stock Price Increases Over 20%: Why It Happened
The stock price of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is trading at over 20% today. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports